Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Top Performance

Predictions

buy
Bayer AG

Start price
Target price
Perf. (%)
€26.78
11.03.24
€28.00
11.03.25
6.63%
28.03.24

Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Traumtanz 
11.03.24 50%
buy
Bayer AG

Start price
Target price
Perf. (%)
€26.32
05.03.24
-
05.03.25
6.69%
06.05.24

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Growths faster than the competition
Significant cyclical dependencies
fenjal 
05.03.24 50%
sell
Bayer AG

Start price
Target price
Perf. (%)
€28.75
21.02.24
-
21.03.24
-6.87%
11.03.24

Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Traumtanz 
21.02.24 50%
buy
Carl Zeiss Meditec AG

Start price
Target price
Perf. (%)
€110.70
10.02.24
-
10.02.25
0.54%
15.02.24

Dirk1 
10.02.24 50%
buy
Bristol-Myers Squibb

Start price
Target price
Perf. (%)
€40.91
02.02.24
-
-
03.02.24

Could be worthwhile Investment >10% per year
blaugold 
02.02.24 50%
buy
Grifols S.A.

Start price
Target price
Perf. (%)
€9.54
09.01.24
-
09.01.25
24.03%
10.01.24

Could be worthwhile Investment >10% per year
Good culture
Few uniques
me8 
09.01.24 0%
buy
Bayer AG

Start price
Target price
Perf. (%)
€35.35
05.01.24
-
0.00%
05.01.24

Could be worthwhile Investment >10% per year
daimler1 
05.01.24 50%
buy
Bristol-Myers Squibb

Start price
Target price
Perf. (%)
€47.60
05.01.24
-
05.01.25
0.63%
05.03.24

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
High dividend yield expected
Good rating
fenjal 
05.01.24 50%
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€75.96
02.01.24
€80.00
02.02.24
-6.29%
22.01.24

Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
RudolfL 
02.01.24 50%
buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€529.00
18.12.23
€558.00
18.12.24
6.62%
06.01.24

Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Traumtanz 
18.12.23 50%
sell
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€526.00
14.12.23
€558.00
14.12.24
0.57%
18.12.23

Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Traumtanz 
14.12.23 50%
buy
Bayer AG

Start price
Target price
Perf. (%)
€31.93
08.12.23
-
08.12.24
0.11%
08.12.23

Could be very worthwhile Investment >20% year
bundfuture 
08.12.23 50%
buy
Bayer AG

Start price
Target price
Perf. (%)
€32.00
07.12.23
€38.00
07.12.24
-15.23%
26.03.24

Undervalued
Well known brand
Future proof or reliable business model
Top 10 in its market
Snowman 
07.12.23 50%
sell
Bayer AG

Start price
Target price
Perf. (%)
€32.77
24.11.23
€35.00
21.12.23
-6.78%
29.11.23

Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Traumtanz 
24.11.23 50%
buy
Bayer AG

Start price
Target price
Perf. (%)
€33.84
21.11.23
€35.00
21.12.23
-3.16%
24.11.23

Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Traumtanz 
21.11.23 50%
buy
Bayer AG

Start price
Target price
Perf. (%)
€34.23
20.11.23
€42.00
20.11.24
-6.50%
07.12.23

Undervalued
Well known brand
Future proof or reliable business model
Top 10 in its market
Snowman 
20.11.23 50%
sell
Bayer AG

Start price
Target price
Perf. (%)
€40.83
15.11.23
€35.00
15.11.24
-19.02%
22.11.23

Probably not worthwhile Investment
Higher risks for its business
kschabe 
15.11.23 60%
buy
Exact Sciences

Start price
Target price
Perf. (%)
€55.41
11.11.23
€105.00
11.12.23
7.56%
25.11.23

Revenue growth >5% per year expected
Rising EBIT margin expected
Standard Investments for future growth
negative Cash Flow expected
miromb 
11.11.23 50%
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€75.86
04.11.23
€89.00
04.12.23
-4.82%
05.12.23

Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
RudolfL 
04.11.23 50%
buy
Bayer AG

Start price
Target price
Perf. (%)
€40.81
31.10.23
-
31.10.24
-18.31%
20.11.23

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Growths faster than the competition
Significant cyclical dependencies
fenjal 
31.10.23 50%
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€126.60
29.10.23
€150.00
31.03.26
-
30.10.23

Could be very worthwhile Investment >20% year
BiotechBee 
29.10.23 50%
buy
Teva Pharmaceutical Industries Ltd ADR

Start price
Target price
Perf. (%)
€7.68
23.10.23
-
23.10.24
10.16%
06.11.23

Top 10 in its market
Future proof or reliable business model
fenjal 
23.10.23 50%
buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€568.50
11.10.23
€558.00
11.10.24
-7.48%
14.12.23

Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Traumtanz 
11.10.23 50%
buy
Fresenius Medical Care AG & Co KGaA ST

Start price
Target price
Perf. (%)
€33.12
11.10.23
-
11.10.24
14.79%
12.12.23

Known brand
Could be worthwhile Investment >10% per year
fenjal 
11.10.23 50%
sell
Fresenius Medical Care AG & Co KGaA ST

Start price
Target price
Perf. (%)
€38.99
04.10.23
€22.00
04.10.24
-16.75%
14.10.23

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
kostojunior 
04.10.23 0%